Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts Tristán, Ana Isabel Jiménez Luna, Cristina Abreu, Ana Cristina Arrabal-Campos, Francisco Manuel Salmerón, Ana del Mar Rodríguez, Firma Isabel Rodriguez-Maresca, Manuel Angel Bernardino García, Antonio Melguizo Alonso, Consolación Prados Salazar, José Carlos Fernández, Ignacio COVID-19 Metabolomics NMR The COVID-19 pandemic remains a significant global health threat, with uncertainties persisting regarding the factors determining whether individuals experience mild symptoms, severe conditions, or succumb to the disease. This study presents an NMR metabolomics-based approach, analysing 80 serum and urine samples from COVID-19 patients (34 intensive care patients and 46 hospitalized patients) and 32 from healthy controls. Our research identifies discriminant metabolites and clinical variables relevant to COVID-19 diagnosis and severity. These discriminant metabolites play a role in specific pathways, mainly “Phenylalanine, tyrosine and tryptophan biosynthesis”, “Phenylalanine metabolism”, “Glycerolipid metabolism” and “Arginine and proline metabolism”. We propose a three-metabolite diagnostic panel—comprising isoleucine, TMAO, and glucose—that effectively discriminates COVID-19 patients from healthy individuals, achieving high efficiency. Furthermore, we found an optimal biomarker panel capable of efficiently classify disease severity considering both clinical characteristics (obesity/overweight, dyslipidemia, and lymphocyte count) together with metabolites content (ethanol, TMAO, tyrosine and betaine). 2024-11-18T11:21:21Z 2024-11-18T11:21:21Z 2024-10-10 journal article Tristá, A.I. et. al. Sci Rep 14, 23713 (2024). [https://doi.org/10.1038/s41598-024-74641-9] https://hdl.handle.net/10481/97006 10.1038/s41598-024-74641-9 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Springer Nature